SCHEMBL1591669

SCHEMBL1591669

Cc1cc(Oc2ccc(NS(=O)(=O)c3ccc(Cl)s3)cc2)c2cc(F)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ LMNA P02545 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ PABPC1 P11940 1/20 0.45
▸ PTPN1 P18031 9/20 0.44
▸ PTPN2 P17706 8/20 0.44
▸ PTPN5 P54829 8/20 0.44
▸ HSPD1 P10809 5/20 0.43
▸ HSPE1 P61604 5/20 0.43
▸ KIT P10721 1/20 0.43
▸ CASP3 P42574 2/20 0.42
▸ SENP8 Q96LD8 2/20 0.42
▸ SENP7 Q9BQF6 2/20 0.42
▸ SENP6 Q9GZR1 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592072 0.83 PGR (0.55) —
SCHEMBL10328527 0.82 LMNA (0.53) SMN1; SMN2LMNAMEN1KMT2AMAPT
SCHEMBL1591224 0.82 FFAR1 (0.56) MAPT
SCHEMBL1591137 0.82 PGR (0.50) SMN1; SMN2LMNAMEN1KMT2AMAPT
SCHEMBL1591801 0.82 GHSR (0.46) LMNAMEN1KMT2AMAPTNPC1
SCHEMBL1592197 0.81 RORC (0.51) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL1591277 0.80 ATM (0.44) SMN1; SMN2LMNAMEN1KMT2AMAPT
SCHEMBL1592203 0.79 AXL (0.47) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL1591817 0.79 ACLY (0.52) —
SCHEMBL1591770 0.78 ACLY (0.45) SMN1; SMN2LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US claimed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
US-9206130-B2 Quinoline derivatives as AXL kinase inhibitors MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-12-08 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092503-A1 QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS AXL, FLT3, TYRO3 SMN1; SMN2 4340/4885LMNA 4138/4885MEN1 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback